Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4171410 | 0.86 | GPR119 (0.43) | GPR119FAAH | |
| SCHEMBL4155145 | 0.85 | GPR119 (0.43) | GPR119 | |
| SCHEMBL4151122 | 0.83 | DPP4 (0.39) | GPR119 | |
| SCHEMBL31735374 | 0.83 | KDM4E (0.41) | GPR119 | |
| SCHEMBL15521929 | 0.77 | ALDH1A1 (0.45) | GPR119 | |
| SCHEMBL4002091 | 0.73 | GPR119 (0.48) | GPR119FAAH | |
| SCHEMBL20476727 | 0.73 | GPR119 (0.43) | GPR119FAAH | |
| SCHEMBL31735869 | 0.73 | PIK3CA (0.39) | GPR119 | |
| SCHEMBL15522269 | 0.72 | ALDH1A1 (0.48) | GPR119 | |
| SCHEMBL4008933 | 0.72 | GPR119 (0.47) | GPR119FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8084466-B2 | Bicyclic heteroaryl-substituted imidazoles as modulators of the histamine H4 receptor | JANSSEN PHARMACEUTICA NV (BE) | 2011-12-27 | — | — | US | disclosed |
| WO-2009079001-A1 | BICYCLIC HETEROARYL-SUBSTITUTED IMIDAZOLES AS MODULATORS OF THE HISTAMINE H4 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-06-25 | — | — | WO | disclosed |
| US-20090156613-A1 | Bicyclic heteroaryl-substituted imidazoles as modulators of the histamine H4 receptor | KINDRACHUK DAVID E | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156613-A1 | Bicyclic heteroaryl-substituted imidazoles as modulators of the histamine H4 receptor | HRH4, HRH3, HRH1 | GPR119 377/4885FAAH 345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.